Johnson & Johnson (NYSE:JNJ) Holdings Boosted by Loudon Investment Management LLC

Loudon Investment Management LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,922 shares of the company’s stock after purchasing an additional 290 shares during the quarter. Loudon Investment Management LLC’s holdings in Johnson & Johnson were worth $864,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Houlihan Financial Resource Group Ltd. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $1,376,000. Bowen Hanes & Co. Inc. lifted its stake in shares of Johnson & Johnson by 11.5% in the 4th quarter. Bowen Hanes & Co. Inc. now owns 362,432 shares of the company’s stock valued at $52,868,000 after purchasing an additional 37,290 shares during the last quarter. Community Financial Services Group LLC lifted its stake in shares of Johnson & Johnson by 2.6% in the 4th quarter. Community Financial Services Group LLC now owns 25,571 shares of the company’s stock valued at $3,730,000 after purchasing an additional 645 shares during the last quarter. Csenge Advisory Group lifted its stake in shares of Johnson & Johnson by 18.7% in the 4th quarter. Csenge Advisory Group now owns 13,480 shares of the company’s stock valued at $1,966,000 after purchasing an additional 2,127 shares during the last quarter. Finally, Grandfield & Dodd LLC lifted its position in Johnson & Johnson by 1.8% during the 4th quarter. Grandfield & Dodd LLC now owns 98,632 shares of the company’s stock worth $14,387,000 after acquiring an additional 1,720 shares during the last quarter. Institutional investors own 69.30% of the company’s stock.

Shares of JNJ stock traded up $3.24 during trading hours on Wednesday, reaching $122.42. 7,032,822 shares of the company’s stock were exchanged, compared to its average volume of 15,632,667. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $154.50. The stock has a market capitalization of $293.00 billion, a P/E ratio of 18.06, a P/E/G ratio of 1.85 and a beta of 0.74. The business has a fifty day moving average price of $141.31 and a 200-day moving average price of $138.39. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.01. Johnson & Johnson had a return on equity of 39.27% and a net margin of 22.18%. The company had revenue of $20.75 billion during the quarter, compared to analyst estimates of $20.83 billion. During the same period in the previous year, the company earned $1.97 earnings per share. The company’s quarterly revenue was up 1.7% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 9.03 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 25th were issued a dividend of $0.95 per share. The ex-dividend date was Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 3.10%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 43.78%.

A number of equities research analysts have issued reports on JNJ shares. Cantor Fitzgerald restated a “buy” rating and set a $168.00 price target on shares of Johnson & Johnson in a report on Thursday, January 23rd. Wells Fargo & Co boosted their price objective on Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a research report on Thursday, January 9th. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 target price for the company in a research note on Wednesday, December 18th. Citigroup started coverage on Johnson & Johnson in a report on Wednesday, March 4th. They issued a “buy” rating and a $163.00 target price on the stock. Finally, Morgan Stanley raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $145.00 to $170.00 in a report on Tuesday, December 17th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $162.33.

In other news, Director William D. Perez bought 500 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average cost of $127.69 per share, for a total transaction of $63,845.00. Following the completion of the purchase, the director now owns 16,030 shares of the company’s stock, valued at approximately $2,046,870.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Michael E. Sneed sold 58,128 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $149.39, for a total value of $8,683,741.92. Following the completion of the transaction, the chief operating officer now owns 107,511 shares of the company’s stock, valued at $16,061,068.29. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: What is the price-to-earnings growth (PEG) ratio?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.